Meredith Bryarly1, Satish R Raj1, Lauren Phillips1, Linda S Hynan1, Luis E Okamoto1, Amy C Arnold1, Sachin Y Paranjape1, Megan Vernino1, Bonnie K Black1, Steven Vernino1. 1. Department of Neurology (MB, LP, MV, SV), UT Southwestern Medical Center, Dallas; Autonomic Dysfunction Center (SRR, LEO, ACA, SYP, BKB), Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; Neural & Behavioral Sciences (ACA), Pennsylvania State University College of Medicine, Hershey; Department of Cardiac Sciences (SRR), Libin Cardiovascular Institute of Alberta, University of Calgary, Canada; and Departments of Population & Data Sciences and Psychiatry (LSH), UT Southwestern Medical Center, Dallas.
Abstract
OBJECTIVE: Postural tachycardia syndrome (POTS), the most common form of dysautonomia, may be associated with autoimmunity in some cases. Autoantibodies against the ganglionic acetylcholine receptor (gAChR) have been reported in a minority of patients with POTS, but the prevalence and clinical relevance is unclear. METHODS: Clinical information and serum samples were systematically collected from participants with POTS and healthy control volunteers (n = 294). The level of positive gAChR antibodies was classified as very low (0.02-0.05 nmol/L), low (0.05-0.2 nmol/L), and high (>0.2 nmol/L). RESULTS: Fifteen of 217 patients with POTS (7%) had gAChR antibodies (8 very low and 7 low). Six of the 77 healthy controls (8%) were positive (3 very low and 3 low). There were no clinical differences between seropositive and seronegative patients with POTS. CONCLUSIONS: Prevalence of gAChR antibody did not differ between POTS and healthy controls, and none had high antibody levels. Patients with POTS were not clinically different based on seropositivity. Low levels of gAChR antibodies are not clinically important in POTS.
OBJECTIVE: Postural tachycardia syndrome (POTS), the most common form of dysautonomia, may be associated with autoimmunity in some cases. Autoantibodies against the ganglionic acetylcholine receptor (gAChR) have been reported in a minority of patients with POTS, but the prevalence and clinical relevance is unclear. METHODS: Clinical information and serum samples were systematically collected from participants with POTS and healthy control volunteers (n = 294). The level of positive gAChR antibodies was classified as very low (0.02-0.05 nmol/L), low (0.05-0.2 nmol/L), and high (>0.2 nmol/L). RESULTS: Fifteen of 217 patients with POTS (7%) had gAChR antibodies (8 very low and 7 low). Six of the 77 healthy controls (8%) were positive (3 very low and 3 low). There were no clinical differences between seropositive and seronegative patients with POTS. CONCLUSIONS: Prevalence of gAChR antibody did not differ between POTS and healthy controls, and none had high antibody levels. Patients with POTS were not clinically different based on seropositivity. Low levels of gAChR antibodies are not clinically important in POTS.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Robert S Sheldon; Blair P Grubb; Brian Olshansky; Win-Kuang Shen; Hugh Calkins; Michele Brignole; Satish R Raj; Andrew D Krahn; Carlos A Morillo; Julian M Stewart; Richard Sutton; Paola Sandroni; Karen J Friday; Denise Tessariol Hachul; Mitchell I Cohen; Dennis H Lau; Kenneth A Mayuga; Jeffrey P Moak; Roopinder K Sandhu; Khalil Kanjwal Journal: Heart Rhythm Date: 2015-05-14 Impact factor: 6.343
Authors: Jeremy K Cutsforth-Gregory; Andrew McKeon; Elizabeth A Coon; David M Sletten; Mariana Suarez; Paola Sandroni; Wolfgang Singer; Eduardo E Benarroch; Robert D Fealey; Phillip A Low Journal: Mayo Clin Proc Date: 2018-08-28 Impact factor: 7.616
Authors: Mark J Thieben; Paola Sandroni; David M Sletten; Lisa M Benrud-Larson; Robert D Fealey; Steven Vernino; Vanda A Lennon; Win-Kuang Shen; Phillip A Low Journal: Mayo Clin Proc Date: 2007-03 Impact factor: 7.616
Authors: Meredith Bryarly; Lauren T Phillips; Qi Fu; Steven Vernino; Benjamin D Levine Journal: J Am Coll Cardiol Date: 2019-03-19 Impact factor: 24.094
Authors: Artur Fedorowski; Satish R Raj; Juliette Hall; Kate M Bourne; Steven Vernino; Viktor Hamrefors; Isabella Kharraziha; Jan Nilsson; Robert S Sheldon Journal: Circulation Date: 2022-06-29 Impact factor: 39.918